These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26678555)

  • 1. Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.
    Verbeken G; Huys I; De Vos D; De Coninck A; Roseeuw D; Kets E; Vanderkelen A; Draye JP; Rose T; Jennes S; Ceulemans C; Pirnay JP
    FEMS Microbiol Lett; 2016 Feb; 363(4):. PubMed ID: 26678555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.
    Verbeken G; Pirnay JP; De Vos D; Jennes S; Zizi M; Lavigne R; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):161-72. PubMed ID: 22527355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Call for a dedicated European legal framework for bacteriophage therapy.
    Verbeken G; Pirnay JP; Lavigne R; Jennes S; De Vos D; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2014 Apr; 62(2):117-29. PubMed ID: 24500660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage Production in Compliance with Regulatory Requirements.
    Pirnay JP; Merabishvili M; Van Raemdonck H; De Vos D; Verbeken G
    Methods Mol Biol; 2018; 1693():233-252. PubMed ID: 29119444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality and safety requirements for sustainable phage therapy products.
    Pirnay JP; Blasdel BG; Bretaudeau L; Buckling A; Chanishvili N; Clark JR; Corte-Real S; Debarbieux L; Dublanchet A; De Vos D; Gabard J; Garcia M; Goderdzishvili M; Górski A; Hardcastle J; Huys I; Kutter E; Lavigne R; Merabishvili M; Olchawa E; Parikka KJ; Patey O; Pouilot F; Resch G; Rohde C; Scheres J; Skurnik M; Vaneechoutte M; Van Parys L; Verbeken G; Zizi M; Van den Eede G
    Pharm Res; 2015 Jul; 32(7):2173-9. PubMed ID: 25585954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European regulatory conundrum of phage therapy.
    Verbeken G; De Vos D; Vaneechoutte M; Merabishvili M; Zizi M; Pirnay JP
    Future Microbiol; 2007 Oct; 2(5):485-91. PubMed ID: 17927471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The next generation of bacteriophage therapy.
    Lu TK; Koeris MS
    Curr Opin Microbiol; 2011 Oct; 14(5):524-31. PubMed ID: 21868281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of the Eliava Institute in bacteriophage therapy.
    Kutateladze M
    Virol Sin; 2015 Feb; 30(1):80-1. PubMed ID: 25662889
    [No Abstract]   [Full Text] [Related]  

  • 10. The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.
    Faltus T
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy regulation.
    Verbeken G; Huys I; Ceulemans C; Jennes S; De Vos D; Pirnay JP
    Burns; 2016 Feb; 42(1):11-12. PubMed ID: 26702564
    [No Abstract]   [Full Text] [Related]  

  • 12. Taking bacteriophage therapy seriously: a moral argument.
    Verbeken G; Huys I; Pirnay JP; Jennes S; Chanishvili N; Scheres J; Górski A; De Vos D; Ceulemans C
    Biomed Res Int; 2014; 2014():621316. PubMed ID: 24868534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic bacteriophages as a rescue treatment for drug-resistant infections - an in vivo studies overview.
    Kwiatek M; Parasion S; Nakonieczna A
    J Appl Microbiol; 2020 Apr; 128(4):985-1002. PubMed ID: 31778593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial bioagents based on principles of bacteriophage biology: an overview.
    Knoll BM; Mylonakis E
    Clin Infect Dis; 2014 Feb; 58(4):528-34. PubMed ID: 24270166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriophages as therapeutic agents.
    Sulakvelidze A; Morris JG
    Ann Med; 2001 Nov; 33(8):507-9. PubMed ID: 11730156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From medical tradition to traditional medicine: A Tibetan formula in the European framework.
    Schwabl H; Vennos C
    J Ethnopharmacol; 2015 Jun; 167():108-14. PubMed ID: 25446636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
    Kuhlmann-Gottke J; Duchow K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriophage biocontrol in animals and meat products.
    Atterbury RJ
    Microb Biotechnol; 2009 Nov; 2(6):601-12. PubMed ID: 21255295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.